Zymeworks Inc. (ZYME)
NASDAQ: ZYME · Real-Time Price · USD
16.92
+0.24 (1.44%)
Oct 9, 2025, 4:00 PM EDT - Market closed
Zymeworks Employees
As of December 31, 2024, Zymeworks had 286 total employees, including 280 full-time and 6 part-time employees. The number of employees increased by 8 or 2.88% compared to the previous year.
Employees
286
Change (1Y)
8
Growth (1Y)
2.88%
Revenue / Employee
$429,605
Profits / Employee
-$257,605
Market Cap
1.27B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 286 | 8 | 2.88% |
| Dec 31, 2023 | 278 | -16 | -5.44% |
| Dec 31, 2022 | 294 | -164 | -35.81% |
| Dec 31, 2021 | 458 | 103 | 29.01% |
| Dec 31, 2020 | 355 | 99 | 38.67% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ZYME News
- 21 hours ago - InMed Pharmaceuticals Appoints Mr. Neil Klompas to It's Board of Directors - Newsfile Corp
- 1 day ago - Zymeworks Appoints Dr. Adam Schayowitz as Acting Chief Development Officer - GlobeNewsWire
- 5 weeks ago - Zymeworks: Despite T-Cell Engager Setback, ADC Candidates Press On - Seeking Alpha
- 5 weeks ago - Zymeworks Pulls Plug On Early-Stage Cancer Potential As Therapy Unlikely To Provide Benefit - Benzinga
- 5 weeks ago - Zymeworks halts development of cancer drug after trial setback - Reuters
- 5 weeks ago - Zymeworks Announces Decision to Discontinue Clinical Development of ZW171, a Mesothelin-directed T cell Engager - GlobeNewsWire
- 7 weeks ago - Zymeworks Announces Participation in Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry - GlobeNewsWire